Biocytogen Pharmaceuticals (Beijing) (HKG:2315) expects to record a net profit between 20 million yuan and 40 million yuan for 2024, against a loss of 383 million yuan logged for 2023, a Monday Hong Kong bourse filing said.
The pharmaceutical company attributed the expected turnaround to a rapid increase in sales revenue and high gross profit margins from increased sales of antibody molecules to overseas customers, domestic and overseas growth in gene editing animal model business, cost control, and reduced research and development expenses during the reporting year.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。